We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IX:NYSEORIX Corporation Analysis

Data as of 2026-05-25 - not real-time

$38.85

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

ORIX shares are trading well above the 20‑day, 50‑day and 200‑day moving averages, confirming a strong bullish trend. The MACD line sits comfortably above its signal line, while the RSI has climbed into overbought territory, indicating momentum that could sustain near‑term upside. Current price sits just below the recent resistance level, with a solid support cushion well above the 30‑day low, and volume has remained stable despite a 38% 30‑day volatility. The computed beta near unity suggests market‑aligned price movement, and the discounted cash‑flow model points to a modest upside of roughly 5 %.
Fundamentally, the company posted a record net income for the fiscal year ended March 2026 and raised its profit target, driven by asset disposals and accelerated cash returns. A forward P/E of just over three versus an industry average of 16.8 signals significant undervaluation, while the trailing P/E sits comfortably below peers. The dividend yield of 2.58% is backed by a low 22% payout ratio and a balance sheet with cash far exceeding total debt, despite a high debt‑to‑equity ratio. Management’s guidance and recent news of strategic divestitures reinforce a growth narrative that complements the attractive valuation and sustainable dividend profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Price near short‑term resistance with overbought RSI
  • Strong bullish technical alignment (MACD, SMAs)
  • Stable volume and moderate volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Record earnings and upward profit guidance
  • Significant valuation gap (forward P/E ~3)
  • Sustainable dividend and net‑cash position

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Diversified global financial operations reducing concentration risk
  • Continued asset disposals and cash returns boosting ROE
  • Undervalued relative to peers with upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth28.00%
Profit Margin13.43%
P/E Ratio15.5
ROE10.42%
ROA2.40%
Debt/Equity141.40
P/B Ratio1.5
Op. Cash Flow$1369.6B
Free Cash Flow$-1643793743872
Industry P/E16.8

Technical Analysis

TrendBullish
RSI71.7
Support$31.48
Resistance$39.38
MA 20$35.36
MA 50$32.44
MA 200$29.30
MACDBullish
VolumeStable
Fear & Greed Index91.61

Valuation

Fair Value$25,963.42
Target Price$38.87
Upside/Downside0.06%
GradeUndervalued
TypeBlend
Dividend Yield2.58%

Risk Assessment

Beta1.00
Volatility38.14%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.